MCUJF

Medicure Inc. [MCUJF] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

MCUJF Stock Summary

Top 10 Correlated ETFs

MCUJF


Top 10 Correlated Stocks

MCUJF


In the News

11:02 08 Dec 2022 MCUJF

Medicure Inc. (MCUJF) Q3 2022 Earnings Call Transcript

Medicure Inc. (OTCPK:MCUJF) Q3 2022 Results Conference Call November 25, 2022 8:30 AM ET Company Participants Dr. Albert Friesen - CEO Dr. Neil Owens - President and COO Haaris Uddin - CFO Conference Call Participants Kurt Caramanidis - Carl M. Hennig, Inc. Operator Good morning, ladies and gentlemen and welcome to Medicure's Earnings Conference Call for the Quarter Ended September 30, 2022.

05:00 08 Dec 2022 MCUJF

MEDICURE TO PRESENT FINANCIAL RESULTS ON NOVEMBER 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED SEPTEMBER 30, 2022

WINNIPEG, MB , Nov. 17, 2022 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the Q3 Financial Results on a Conference Call on November 25, 2022 at 8:30 am Eastern Time. The Q3 Financials will be filed after closing the day before.

05:00 08 Dec 2022 MCUJF

MEDICURE TO PRESENT FINANCIAL RESULTS ON AUGUST 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED JUNE 30, 2022

WINNIPEG, MB , Aug. 17, 2022 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the Q2 Financial Results on a Conference Call on August 25, 2022 at 8:30 am Eastern Time. The Q2 Financials will be filed after closing the day before.

01:00 08 Dec 2022 MCUJF

MEDICURE TO REPORT FINANCIAL RESULTS FOR YEAR ENDED DECEMBER 31, 2021 ON APRIL 28TH AT 7:30 AM CST

WINNIPEG, MB , April 26, 2022 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today announces Medicure's 2021 Year End Results Conference Call. Conference Call Info: Topic: Medicure's 2021 Year End Results Call date:  Thursday, April 28, 2022 Time: 7:30 AM Central Time (8:30 AM Eastern Time) Canada toll: 1 (416) 764-8659 North American toll-free:  1 (888) 664-6392 Passcode:  not required   Webcast:    This conference call will be webcast live over the internet and can be accessed from the Medicure investor relations page at the following link: www.medicure.com/investors You may request international country-specific access information by e-mailing the Company in advance.

09:26 08 Dec 2022 MCUJF

MedX Health launches DermSecure screening services at Medicure clinic in Mississauga, Ontario

MedX Health Corp revealed that it is now offering its DermSecure screening services at the Medicure (TSX-V:MPH) clinic in Mississauga, Ontario - the first launch of its platform in a blended physician and pharmacy clinic setting in Canada. Under the tie-up, Medx's scanning services are now available to the clinic's 5,000 existing family physician patients as well as walk-in patients through the on-site pharmacy.

09:50 08 Dec 2022 MCUJF

Medicure Inc. (MCUJF) CEO Albert Friesen on Q2 2021 Results - Earnings Call Transcript

Medicure Inc. (MCUJF) CEO Albert Friesen on Q2 2021 Results - Earnings Call Transcript

05:00 08 Dec 2022 MCUJF

Medicure Reports Financial Results for the Second Quarter Ended June 30, 2021

WINNIPEG, MB, Aug. 27, 2021 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended June 30, 2021.  Quarter Ended June 30, 2021 Highlights: Recorded total net revenue from the sale of products of $5.09 million during the second quarter ended June 30, 2021 compared to $2.68 million for the second quarter ended June 30, 2020; Recorded total net revenue from the sale of AGGRASTAT® of $2.8 million during the second quarter ended June 30, 2021 compared to $2.6 million for the second quarter ended June 30, 2020; Net loss for the second quarter ended June 30, 2021 was $639,000 compared to net income of $19,000 for the second quarter ended June 30, 2020; Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA1) for the second quarter ended June 30, 2021 was $158,000 compared to adjusted EBITDA of $263,000 for the second quarter ended June 30, 2020 Financial Results Net revenues for the three months ended June 30, 2021 were $5.09 million compared to $2.68 million for the three months ended June 30, 2020.

08:00 08 Dec 2022 MCUJF

Medicure Announces Grant of Stock Options

WINNIPEG, MB, July 30, 2021 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, announced today that it has granted stock options (the "Options") to certain officers of the Company to purchase a total of 90,000 common shares at a price of $1.10 per common share. The Options, which vest immediately, are exercisable for a period of five years and have been granted in accordance with the terms of the Company's current stock option plan.

05:01 08 Dec 2022 MCUJF

Medicure Announces Appointment of David Gurvey as Chief Financial Officer

WINNIPEG, MB, June 24, 2021 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, is pleased to announce the appointment of Mr. David Gurvey (CPA, CMA, B.Sc.

04:20 08 Dec 2022 MCUJF

Medicure Inc.(MCUJF) CEO Albert Friesen on Q1 2021 Results - Earnings Call Transcript

Medicure Inc.(MCUJF) CEO Albert Friesen on Q1 2021 Results - Earnings Call Transcript

MCUJF Financial details

Company Rating
Buy
Market Cap
8.35M
Income
2.82M
Revenue
23.55M
Book val./share
2.04
Cash/share
0.44
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
25 Nov 2022
P/E
13.33
Forward P/E
-
PEG
-1.07
P/S
0.44
P/B
0.49
P/C
1.82
P/FCF
3.8
Quick Ratio
1.28
Current Ratio
1.86
Debt / Equity
0.03
LT Debt / Equity
0.03
-
-
EPS (TTM)
0.16
EPS next Y
-
EPS next Q
-
EPS this Y
-89.06%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-4.33%
Revenue Q/Q
-8%
EPS Q/Q
-283.33%
-
-
-
-
SMA20
1.22%
SMA50
6.41%
SMA100
9.21%
Inst Own
-
Inst Trans
-
ROA
9%
ROE
15%
ROC
0.05%
Gross Margin
66%
Oper. Margin
5%
Profit Margin
12%
Payout
-
Shs Outstand
10.25M
Shs Float
5.15M
-
-
-
-
Target Price
-
52W Range
0.64-1.1
52W High
-
52W Low
-
RSI
42.37
Rel Volume
-
Avg Volume
1.33K
Volume
Perf Week
-8.05%
Perf Month
-13.04%
Perf Quarter
-20%
Perf Half Y
-20.79%
-
-
-
-
Beta
0.84017
-
-
Volatility
0.03%, 0.05%
Prev Close
0%
Price
0.8
Change
0%

MCUJF Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
1.741.841.341.092.12
Net income per share
2.780.25-1.32-0.64-0.07
Operating cash flow per share
1.40.05-0.98-0.210.39
Free cash flow per share
1.32-0.05-1.9-0.210.31
Cash per share
0.344.550.860.250.36
Book value per share
5.175.291.81.791.8
Tangible book value per share
5.055.191.160.240.41
Share holders equity per share
5.175.291.81.791.8
Interest debt per share
0.0100.070.140.12
Market cap
116.31M96.7M54.05M16.97M10.72M
Enterprise value
111.05M72.56M42.17M15.7M8.2M
P/E ratio
2.6824.63-2.73-2.48-14.75
Price to sales ratio
4.293.322.681.460.49
POCF ratio
5.31130.28-3.69-7.572.69
PFCF ratio
5.65-131.43-1.9-7.573.38
P/B Ratio
1.441.162.010.890.58
PTB ratio
1.441.162.010.890.58
EV to sales
4.092.492.091.350.38
Enterprise value over EBITDA
2.6314.17-2.38-3.853.38
EV to operating cash flow
5.0797.76-2.88-7.012.05
EV to free cash flow
5.39-98.62-1.48-72.58
Earnings yield
0.370.04-0.37-0.4-0.07
Free cash flow yield
0.18-0.01-0.53-0.130.3
Debt to equity
000.030.060.04
Debt to assets
0.370.190.360.440.35
Net debt to EBITDA
-0.12-4.710.670.31-1.04
Current ratio
2.625.292.691.271.47
Interest coverage
40.62000-55.08
Income quality
0.50.190.740.33-5.49
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00.670.170.390.12
Research and developement to revenue
0.190.230.220.280.08
Intangibles to total assets
0.010.020.230.490.5
Capex to operating cash flow
-0.06-1.990.950-0.21
Capex to revenue
-0.05-0.05-0.690-0.04
Capex to depreciation
-0.17-4.94-7.20-0.26
Stock based compensation to revenue
0.020.040.020.030.01
Graham number
17.985.447.35.081.69
ROIC
0.04-0.01-0.27-0.37-0.11
Return on tangible assets
0.340.04-0.61-0.39-0.05
Graham Net
1.733.920.56-0.53-0.11
Working capital
70.88M72.65M19.7M3.37M4.04M
Tangible asset value
78.95M81.89M17.34M2.56M4.23M
Net current asset value
66.34M69.42M16.02M768K2.56M
Invested capital
000.040.080.06
Average receivables
48.26M8.01M7.73M5.25M4.96M
Average payables
8.68M10.68M8.18M6.98M6.82M
Average inventory
4.11M4.69M5.73M5.14M4.23M
Days sales outstanding
1.23K134.98184.84165.1578.21
Days payables outstanding
1.09K1.26K471.01393.11269.47
Days of inventory on hand
323.95372.65317.62289.47134.53
Receivables turnover
0.32.71.972.214.67
Payables turnover
0.330.290.770.931.35
Inventory turnover
1.130.981.151.262.71
ROE
0.540.05-0.73-0.36-0.04
Capex per share
-0.08-0.09-0.920-0.08

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-03-312021-06-302021-09-302021-12-31 2022-09-30
Revenue per share
0.480.50.480.220.52
Net income per share
-0.1-0.06-0.090.060.11
Operating cash flow per share
0.020.040.110.07-0.01
Free cash flow per share
0.020.010.090.06-0.02
Cash per share
0.280.240.320.120.44
Book value per share
1.751.681.660.592.04
Tangible book value per share
0.230.240.250.130.64
Share holders equity per share
1.751.681.660.592.04
Interest debt per share
0.150.130.120.040.09
Market cap
15.89M12.01M9.95M28.91M8.91M
Enterprise value
14.4M10.85M7.88M26.38M5.37M
P/E ratio
-3.79-4.7-2.633.792
Price to sales ratio
3.222.362.024.251.69
POCF ratio
70.9326.238.7513.32-73.66
PFCF ratio
70.93184.8110.9714.64-38.75
P/B Ratio
0.890.70.581.570.43
PTB ratio
0.890.70.581.570.43
EV to sales
2.922.131.63.881.01
Enterprise value over EBITDA
-436.4436.4-79.5911.615.05
EV to operating cash flow
64.323.686.9312.16-44.34
EV to free cash flow
64.3166.878.6913.36-23.33
Earnings yield
-0.07-0.05-0.10.070.12
Free cash flow yield
0.010.010.090.07-0.03
Debt to equity
0.060.050.050.040.03
Debt to assets
0.440.440.440.350.3
Net debt to EBITDA
45-3.9120.87-1.11-3.34
Current ratio
1.271.271.281.471.86
Interest coverage
-7.6400-4.77-25.82
Income quality
-0.21-0.72-1.21.14-0.11
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.120.110.110.150.2
Research and developement to revenue
0.120.140.10.010.06
Intangibles to total assets
0.490.480.480.50.48
Capex to operating cash flow
00-0.2-0.090.9
Capex to revenue
00-0.05-0.03-0.02
Capex to depreciation
00-0.26-0.4-0.21
Stock based compensation to revenue
0.010.010.02-0.010
Graham number
21.531.860.892.23
ROIC
-0.05-0.04-0.040.020.04
Return on tangible assets
-0.06-0.04-0.060.130.07
Graham Net
-0.5-0.48-0.42-0.040.13
Working capital
3.12M3.01M3.05M4.04M6.57M
Tangible asset value
2.33M2.41M2.56M4.23M6.6M
Net current asset value
636K669K769K2.56M5.24M
Invested capital
0.080.080.070.060.05
Average receivables
5.32M5.66M5.35M5.31M5.64M
Average payables
7.4M7.57M7.24M7.48M7.32M
Average inventory
3.98M3.86M3.54M3.23M3.39M
Days sales outstanding
85.2294.7886.6361.6490.6
Days payables outstanding
303.35300.56272.92198.65410.21
Days of inventory on hand
225.91201.85174.3999.18236.81
Receivables turnover
1.060.951.041.460.99
Payables turnover
0.30.30.330.450.22
Inventory turnover
0.40.450.520.910.38
ROE
-0.06-0.04-0.060.10.05
Capex per share
00-0.02-0.01-0.01

MCUJF Frequently Asked Questions

What is Medicure Inc. stock symbol ?

Medicure Inc. is a CA stock , located in Winnipeg of Mb and trading under the symbol MCUJF

What is Medicure Inc. stock quote today ?

Medicure Inc. stock price is $0.8 today.

Is Medicure Inc. stock public?

Yes, Medicure Inc. is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap